Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Fig. 2

Changes in ALBI score during the disease course. Changes in ALBI scores at baseline and 2, 4, 6, 8, 10, and 12 weeks after ramucirumab administration. The median ALBI scores at baseline and 2, 4, 6, 8, 10, and 12 weeks were − 2.27, − 2.28, − 2.25, − 2.14, − 2.13, − 2.19, and − 2.38, respectively, with no significant change in ALBI scores during the study period (P = 0.358)

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us